FDA-cleared profile

OptimMRI (v2)

Rebrain, SAS

OptimMRI is intended to aid qualified medical professionals in processing, visualizing, and interpreting anatomical structures from medical images. It can process preoperative DICOM-compatible MR images to generate three-dimensional annotated brain models and support localization of the subthalamic nuclei and ventral intermediate nucleus regions with other clinical methods.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
OptimMRI is intended to aid qualified medical professionals in processing, visualizing, and interpreting anatomical structures from medical images. It can process preoperative DICOM-compatible MR images to generate three-dimensional annotated brain models and support localization of the subthalamic nuclei and ventral intermediate nucleus regions with other clinical methods.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Qualified surgeons, radiologists, dentists, radiation professionals, and other trained users for the labeled planning workflow.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Hospital, outpatient, operating-room, dental, interventional, or other labeled planning environments.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
Patient-specific image visualization, segmentation, measurement, modeling, templating, or treatment planning support.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Supported patient images, DICOM metadata, source-image geometry, and user-selected planning inputs.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Segmentations, models, measurements, templates, needle or implant plans, or planning views for review and approval.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
The output is an aid to qualified professionals and does not replace other clinical methods, final localization, or treatment planning. Patient, sequence, anatomy, DICOM, and installed-release limits require local verification.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242054
FDA source Exact FDA submission Checked 2026-08-31
Modality
MRI
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Brain and subthalamic and ventral intermediate nucleus regions
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2024-08-12
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Standards-based DICOM/PACS integration was identified in the FDA submission materials; compatibility with a specific PACS, RIS, EHR, or orchestrator requires confirmation.
Public source Exact FDA submission Checked 2026-08-13

Normalized from the prior exact-submission review. Confirm interface versions and local compatibility during technical evaluation.

Deployment and data flow
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

The exact FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only qualified surgeons, radiologists, dentists, radiation professionals, and other trained users for the labeled planning workflow should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-04
Monitoring and change control
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The output is an aid to qualified professionals and does not replace other clinical methods, final localization, or treatment planning. Patient, sequence, anatomy, DICOM, and installed-release limits require local verification.
FDA source Exact FDA submission Checked 2026-09-04

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K242054 before acceptance. Later family features are not evidence for this exact submission.

exact submission · checked 2026-09-04

Interoperability acceptance

The exact FDA material does not establish a complete interoperability contract. Establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Deployment and security qualification

The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.

exact submission · checked 2026-09-04

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The output is an aid to qualified professionals and does not replace other clinical methods, final localization, or treatment planning. Patient, sequence, anatomy, DICOM, and installed-release limits require local verification.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The output is an aid to qualified professionals and does not replace other clinical methods, final localization, or treatment planning. Patient, sequence, anatomy, DICOM, and installed-release limits require local verification.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The exact FDA 510(k) decision material for K242054 identifies OptimMRI (v2) and describes the indicated use summarized in this dossier. It is regulatory evidence for the exact submission, not independent clinical validation. No performance or outcome claim is promoted without exact product and version linkage.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K242054 FDA decision evidence for OptimMRI (v2)

FDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation. · Brain and subthalamic and ventral intermediate nucleus regions

exact submission · Tested version: OptimMRI (v2) · Sponsor or vendor study

K242054

The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
Public source Not applicable Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K242054 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
10Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact-name and exact-submission searches in the checked indexes returned no PubMed records and no ClinicalTrials.gov records for K242054; no published exact-submission recall was promoted. Candidate literature, registry, and non-native recall records remain quarantined unless exact product, version, and submission linkage is established. The FDA decision material remains the identity and intended-use anchor for OptimMRI (v2). Pricing, complete security architecture, contracted deployment, exact reimbursement, and local interoperability remain unverified. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K253690

LungMaps

Siemens Healthineers AG

LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.

Modality
MRI
Anatomy
Chest/Lung
Decision
2026-06-15
FDA-cleared K260113

uMR Astra

Shanghai United Imaging Healthcare Co., Ltd.

uMR Astra is a diagnostic MR system for cross-sectional and spectroscopic imaging of the labeled head, body, and extremities.

Modality
MRI
Anatomy
Head; body; and extremities
Decision
2026-05-22
FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and...

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27